1
|
Pinto DP, Coutinho DDS, Carvalho KIMD, Ferrero MR, Silva LVD, Silveira GPE, Silva DMD, Araújo JFG, Silva ACA, Pereira HM, Fonseca LBD, Faria RX, Souza MVND, Silva ETD, Santos-Filho OA, Costa JCSD, Amendoeira FC, Martins MA. Pharmacological profiling of JME-173, a novel mexiletine derivative combining dual anti-inflammatory/anti-spasmodic functions and limited action in Na + channels. Eur J Pharmacol 2020; 885:173367. [PMID: 32750364 DOI: 10.1016/j.ejphar.2020.173367] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Revised: 06/30/2020] [Accepted: 07/09/2020] [Indexed: 12/14/2022]
Abstract
Existing evidence suggests that the local anaesthetic mexiletine can be beneficial for patients with asthma. However, caution is required since anaesthesia of the airways inhibits protective bronchodilator neuronal reflexes, limiting applications in conditions of hyperirritable airways. Here, we describe the synthesis of a new series of mexiletine analogues, which were screened for reduced activity in Na+ channels and improved smooth muscle relaxant effects, that were evaluated using the patch-clamp technique and an isolated tracheal organ bath, respectively. JME-173 (1-(4-bromo-3,5-dimethylphenoxy)propan-2-amine) was the most effective among the four mexiletine analogues investigated. JME-173 was then studied in vivo using a murine model of lung inflammation induced by cigarette smoke (CS) and in vitro using neutrophil chemotaxis and mast cell degranulation assays. Finally, the JME-173 pharmacokinetic profile was assessed using HPLC-MS/MS bioanalytical method. JME-173 directly inhibited IL-8 (CXCL8)- and FMLP-induced human neutrophil chemotaxis and allergen-induced mast cell degranulation. After oral administration 1 h before CS exposure, JME-173 (50 mg/kg) strongly reduced the increased number of macrophages and neutrophils recovered in the bronchoalveolar effluent without altering lymphocyte counts. Pharmacokinetic experiments of JME-173 (10 mg/kg, orally) showed values of maximum concentration (Cmax), maximum time (Tmax), area under the blood concentration-time curve (AUC0-t) and area under the blood concentration-time curve from 0-Inf (AUC0-inf) of 163.3 ± 38.3 ng/mL, 1.2 ± 0.3 h, 729.4 ± 118.3 ng*h/ml and 868.9 ± 117.1 ng*h/ml (means ± S.E.M.), respectively. Collectively, these findings suggest that JME-173 has the potential to be an effective oral treatment for diseases associated with bronchoconstriction and inflammation.
Collapse
Affiliation(s)
- Douglas Pereira Pinto
- Laboratory of Pharmacokinetics, Vice Presidency of Research and Innovation in Health - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Diego de Sá Coutinho
- Laboratory of Inflammation, Instituto Oswaldo Cruz - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | | | - Maximiliano R Ferrero
- Laboratory of Inflammation, Instituto Oswaldo Cruz - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Letícia Vallim da Silva
- Laboratory of Pharmacokinetics, Vice Presidency of Research and Innovation in Health - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | | | - Diego Medeiros da Silva
- Laboratory of Pharmacokinetics, Vice Presidency of Research and Innovation in Health - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - João Felipe Garcia Araújo
- Laboratory of Pharmacokinetics, Vice Presidency of Research and Innovation in Health - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Aline C A Silva
- Laboratory of Pharmacokinetics, Vice Presidency of Research and Innovation in Health - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Heliana Martins Pereira
- Laboratory of Pharmacokinetics, Vice Presidency of Research and Innovation in Health - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Laís Bastos da Fonseca
- Laboratory of Pharmacokinetics, Vice Presidency of Research and Innovation in Health - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Robson Xavier Faria
- Laboratory of Toxoplasmosis and Other Protozoans, Oswaldo Cruz Institute, Brazil
| | - Marcus Vinicius Nora de Souza
- Laboratory of Organic Synthesis, Institute of Technology in Drugs, Farmanguinhos - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Emerson Teixeira da Silva
- Laboratory of Organic Synthesis, Institute of Technology in Drugs, Farmanguinhos - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Osvaldo Andrade Santos-Filho
- Laboratory of Molecular Modeling and Computational Structural Biology, Instituto de Pesquisas de Produtos Naturais - Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil
| | | | - Fábio Coelho Amendoeira
- Department of Pharmacology and Toxicology, National Institute of Quality Control in Health - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Marco Aurélio Martins
- Laboratory of Inflammation, Instituto Oswaldo Cruz - Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
| |
Collapse
|